{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T12:41:45Z","timestamp":1767789705690,"version":"3.49.0"},"reference-count":99,"publisher":"Stanford University Press","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Mass Spectrometry and Advances in the Clinical Lab"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jmsacl.2023.04.002","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T18:18:00Z","timestamp":1681409880000},"page":"122-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A customized mass array panel for BCR::ABL1 tyrosine kinase domain mutation screening in chronic myeloid leukemia"],"prefix":"10.21627","volume":"28","author":[{"given":"Nittaya","family":"Limsuwanachot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Budsaba","family":"Rerkamnuaychoke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pimjai","family":"Niparuck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roongrudee","family":"Singdong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adcharee","family":"Kongruang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piyapha","family":"Hirunpatrawong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanaporn","family":"Siriyakorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pa-thai","family":"Yenchitsomanus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teerapong","family":"Siriboonpiputtana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4811","reference":[{"issue":"6","key":"10.1016\/j.jmsacl.2023.04.002_b0005","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.jmsacl.2023.04.002_b0010","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1084\/jem.183.3.811","article-title":"Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr\/Abl","volume":"183","author":"Carlesso","year":"1996","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.jmsacl.2023.04.002_b0015","first-page":"247","article-title":"Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia","volume":"13","author":"Shuai","year":"1996","journal-title":"Oncogene"},{"issue":"25","key":"10.1016\/j.jmsacl.2023.04.002_b0020","doi-asserted-by":"crossref","first-page":"11746","DOI":"10.1073\/pnas.92.25.11746","article-title":"The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation","volume":"92","author":"Raitano","year":"1995","journal-title":"PNAS"},{"issue":"11","key":"10.1016\/j.jmsacl.2023.04.002_b0025","first-page":"1111","article-title":"Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1","volume":"22","author":"Okuda","year":"1994","journal-title":"Exp. Hematol."},{"issue":"6","key":"10.1016\/j.jmsacl.2023.04.002_b0030","first-page":"2343","article-title":"The BCR gene and philadelphia chromosome-positive leukemogenesis","volume":"61","author":"Laurent","year":"2001","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.jmsacl.2023.04.002_b0035","first-page":"M11","article-title":"Bcr-Abl inhibition as a modality of CML therapeutics","volume":"1551","author":"Buchdunger","year":"2001","journal-title":"BBA"},{"issue":"1","key":"10.1016\/j.jmsacl.2023.04.002_b0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI9083","article-title":"Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia","volume":"105","author":"Druker","year":"2000","journal-title":"J. Clin. Invest."},{"issue":"15","key":"10.1016\/j.jmsacl.2023.04.002_b0045","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia\u2013advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.jmsacl.2023.04.002_b0050","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra013339","article-title":"Imatinib mesylate\u2013a new oral targeted therapy","volume":"346","author":"Savage","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.jmsacl.2023.04.002_b0055","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.jmsacl.2023.04.002_b0060","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194820","article-title":"Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia-From Molecular Mechanisms to Clinical Relevance","volume":"13","author":"Alves","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.jmsacl.2023.04.002_b0065","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jmsacl.2023.04.002_b0070","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jmsacl.2023.04.002_b0075","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.jmsacl.2023.04.002_b0080","article-title":"Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance","volume":"461\u201376","author":"Bixby","year":"2009","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"10","key":"10.1016\/j.jmsacl.2023.04.002_b0085","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","article-title":"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review","volume":"34","author":"An","year":"2010","journal-title":"Leuk. Res."},{"issue":"5531","key":"10.1016\/j.jmsacl.2023.04.002_b0090","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.jmsacl.2023.04.002_b0095","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1182\/blood.V95.11.3498","article-title":"Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR\/ABL-transformed hematopoietic cell lines","volume":"95","author":"Weisberg","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jmsacl.2023.04.002_b0100","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","article-title":"Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification","volume":"95","author":"le Coutre","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jmsacl.2023.04.002_b0105","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","article-title":"Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"112","author":"Dulucq","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jmsacl.2023.04.002_b0110","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","article-title":"Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia","volume":"83","author":"Wang","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.jmsacl.2023.04.002_b0115","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1182\/blood-2005-02-0694","article-title":"hOCT 1 and resistance to imatinib","volume":"106","author":"Crossman","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jmsacl.2023.04.002_b0120","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jmsacl.2023.04.002_b0125","doi-asserted-by":"crossref","first-page":"e6124","DOI":"10.1371\/journal.pone.0006124","article-title":"ERK2, but not ERK1, mediates acquired and \u201cde novo\u201d resistance to imatinib mesylate: implication for CML therapy","volume":"4","author":"Aceves-Luquero","year":"2009","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.jmsacl.2023.04.002_b0130","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1038\/s41375-021-01315-0","article-title":"Metabolic alterations mediated by STAT3 promotes drug persistence in CML","volume":"35","author":"Patel","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jmsacl.2023.04.002_b0135","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40199-019-00321-z","article-title":"Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician's perspective","volume":"28","author":"Pushpam","year":"2020","journal-title":"Daru"},{"key":"10.1016\/j.jmsacl.2023.04.002_b0140","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.696960","article-title":"Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia","volume":"12","author":"Kaehler","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jmsacl.2023.04.002_b0145","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.leukres.2017.06.009","article-title":"Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy","volume":"59","author":"Kim","year":"2017","journal-title":"Leuk. Res."},{"issue":"4","key":"10.1016\/j.jmsacl.2023.04.002_b0150","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and Resistance to BCR-ABL1-Targeted Therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.jmsacl.2023.04.002_b0155","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/modpathol.2017.182","article-title":"Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group","volume":"31","author":"Soderquist","year":"2018","journal-title":"Mod. Pathol."},{"issue":"7","key":"10.1016\/j.jmsacl.2023.04.002_b0160","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1177\/1078155221991646","article-title":"Co-existence of BCR-ABL and JAK2V617F mutation in resistant chronic myeloid leukemia in the imatinib era: Is there a correlation?","volume":"27","author":"Frikha","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.jmsacl.2023.04.002_b0165","first-page":"86","article-title":"Concurrent chronic myeloid leukemia and CALR-mutated myeloproliferative neoplasm","volume":"19","author":"Langabeer","year":"2020","journal-title":"EXCLI J."},{"issue":"7","key":"10.1016\/j.jmsacl.2023.04.002_b0170","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJMc1413718","article-title":"A CALR mutation preceding BCR-ABL1 in an atypical myeloproliferative neoplasm","volume":"372","author":"Cabagnols","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jmsacl.2023.04.002_b0175","doi-asserted-by":"crossref","first-page":"e18811","DOI":"10.1097\/MD.0000000000018811","article-title":"Atypical myeloproliferative neoplasm with concurrent BCR-ABL1 fusion and CALR mutation: A case report and literature review","volume":"99","author":"Liu","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.jmsacl.2023.04.002_b0180","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jmsacl.2023.04.002_b0185","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jmsacl.2023.04.002_b0190","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships","volume":"121","author":"Khorashad","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jmsacl.2023.04.002_b0195","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors","volume":"114","author":"Soverini","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jmsacl.2023.04.002_b0200","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1470-2045(07)70379-0","article-title":"Part II: management of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jmsacl.2023.04.002_b0205","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2014.03.003","article-title":"Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia","volume":"11","author":"Balabanov","year":"2014","journal-title":"Drug Discov. Today Technol."},{"issue":"1","key":"10.1016\/j.jmsacl.2023.04.002_b0210","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","article-title":"Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia","volume":"38","author":"Soverini","year":"2014","journal-title":"Leuk. Res."},{"issue":"9","key":"10.1016\/j.jmsacl.2023.04.002_b0215","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.jmsacl.2023.04.002_b0220","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.jmsacl.2023.04.002_b0225","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/blood-2015-08-660977","article-title":"Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients","volume":"127","author":"Deininger","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jmsacl.2023.04.002_b0230","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/hon.894","article-title":"Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent","volume":"27","author":"Kim","year":"2009","journal-title":"Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.jmsacl.2023.04.002_b0235","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000331472","article-title":"Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients","volume":"127","author":"Meggyesi","year":"2012","journal-title":"Acta Haematol."},{"issue":"16","key":"10.1016\/j.jmsacl.2023.04.002_b0240","doi-asserted-by":"crossref","first-page":"21982","DOI":"10.18632\/oncotarget.8010","article-title":"Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients","volume":"7","author":"Soverini","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.jmsacl.2023.04.002_b0245","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/bjh.16382","article-title":"Novel Illumina-based next generation sequencing approach with one-round amplification provides early and reliable detection of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia","volume":"189","author":"Romzova","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jmsacl.2023.04.002_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106728","article-title":"Ultra-deep sequencing mutation analysis of the BCR\/ABL1 kinase domain in newly diagnosed chronic myeloid leukemia patients","volume":"111","author":"Park","year":"2021","journal-title":"Leuk. Res."},{"issue":"8","key":"10.1016\/j.jmsacl.2023.04.002_b0255","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2019002969","article-title":"Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study","volume":"135","author":"Soverini","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jmsacl.2023.04.002_b0260","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00432-014-1845-6","article-title":"Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase","volume":"141","author":"Machova Polakova","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jmsacl.2023.04.002_b0265","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/10428194.2018.1473573","article-title":"Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors","volume":"60","author":"Erbilgin","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"10.1016\/j.jmsacl.2023.04.002_b0270","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.31557\/APJCP.2020.21.7.2003","article-title":"Practical Laboratory Tools for Monitoring of BCR-ABL1 Transcripts and Tyrosine Kinase (TK) Domain Mutations in Chronic Myeloid Leukemia Patients Undergoing TK Inhibitor Therapy: A Single-Center Experience in Thailand","volume":"21","author":"Limsuwanachot","year":"2020","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"1","key":"10.1016\/j.jmsacl.2023.04.002_b0275","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13000-021-01162-8","article-title":"TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome","volume":"16","author":"Niparuck","year":"2021","journal-title":"Diagn. Pathol."},{"issue":"10","key":"10.1016\/j.jmsacl.2023.04.002_b0280","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/10245332.2017.1312736","article-title":"Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients","volume":"22","author":"Limsuwanachot","year":"2017","journal-title":"Hematology"},{"issue":"10","key":"10.1016\/j.jmsacl.2023.04.002_b0285","first-page":"4647","article-title":"Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms","volume":"17","author":"Singdong","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"10","key":"10.1016\/j.jmsacl.2023.04.002_b0290","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1080\/17474086.2020.1813564","article-title":"Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years?","volume":"13","author":"Yilmaz","year":"2020","journal-title":"Expert Rev. Hematol."},{"issue":"1","key":"10.1016\/j.jmsacl.2023.04.002_b0295","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-019-0815-5","article-title":"Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper","volume":"12","author":"Soverini","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jmsacl.2023.04.002_b0300","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bdq.2017.01.001","article-title":"Molecular techniques for the personalised management of patients with chronic myeloid leukaemia","volume":"11","author":"Alikian","year":"2017","journal-title":"Biomol. Detect. Quantif."},{"issue":"3","key":"10.1016\/j.jmsacl.2023.04.002_b0305","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"32","key":"10.1016\/j.jmsacl.2023.04.002_b0310","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1200\/JCO.2011.35.0934","article-title":"Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy","volume":"29","author":"Parker","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.jmsacl.2023.04.002_b0315","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2015-09-666214","article-title":"The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib","volume":"127","author":"Parker","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jmsacl.2023.04.002_b0320","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ajh.22272","article-title":"BCR-ABL1 kinase domain mutations: methodology and clinical evaluation","volume":"87","author":"Alikian","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jmsacl.2023.04.002_b0325","doi-asserted-by":"crossref","first-page":"33429","DOI":"10.1038\/srep33429","article-title":"Potential pitfalls of mass spectrometry to uncover mutations in childhood soft tissue sarcoma: A report from the Children's Oncology Group","volume":"6","author":"Xu","year":"2016","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.jmsacl.2023.04.002_b0330","doi-asserted-by":"crossref","first-page":"75","DOI":"10.21307\/immunohematology-2019-074","article-title":"Blood group genotyping: the power and limitations of the Hemo ID Panel and MassARRAY platform","volume":"31","author":"McBean","year":"2015","journal-title":"Immunohematology"},{"issue":"4","key":"10.1016\/j.jmsacl.2023.04.002_b0335","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.leukres.2013.12.025","article-title":"BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome","volume":"38","author":"Elias","year":"2014","journal-title":"Leuk. Res."},{"issue":"9","key":"10.1016\/j.jmsacl.2023.04.002_b0340","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.26642","article-title":"Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.jmsacl.2023.04.002_b0345","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1182\/blood-2013-03-487728","article-title":"Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain","volume":"122","author":"Soverini","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jmsacl.2023.04.002_b0350","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1756-8722-1-15","article-title":"P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia","volume":"1","author":"Cang","year":"2008","journal-title":"J. Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.jmsacl.2023.04.002_b0355","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1089\/gtmb.2012.0147","article-title":"ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan","volume":"16","author":"Awidi","year":"2012","journal-title":"Genet. Test. Mol. Biomarkers"},{"issue":"10","key":"10.1016\/j.jmsacl.2023.04.002_b0360","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.jmsacl.2023.04.002_b0365","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jmsacl.2023.04.002_b0370","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jmsacl.2023.04.002_b0375","first-page":"4470","article-title":"Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 (T315I)-compound mutations","volume":"11","author":"Gleixner","year":"2021","journal-title":"Am. J. Cancer Res."},{"issue":"11","key":"10.1016\/j.jmsacl.2023.04.002_b0380","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9113671","article-title":"The New ELN Recommendations for Treating CML","volume":"9","author":"Hehlmann","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jmsacl.2023.04.002_b0385","article-title":"Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon frontline therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort study","volume":"33","author":"Dey","year":"2022","journal-title":"Cancer Treat Res Commun."},{"key":"10.1016\/j.jmsacl.2023.04.002_b0390","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s12885-016-2635-0","article-title":"In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants","volume":"16","author":"Soverini","year":"2016","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.jmsacl.2023.04.002_b0395","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/S2352-3026(19)30027-4","article-title":"Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study","volume":"6","author":"Kizilors","year":"2019","journal-title":"Lancet Haematol."},{"issue":"Suppl","key":"10.1016\/j.jmsacl.2023.04.002_b0400","article-title":"NGS in CML - New standard diagnostic procedure?","volume":"3","author":"Branford","year":"2019","journal-title":"Hemasphere."},{"issue":"1","key":"10.1016\/j.jmsacl.2023.04.002_b0405","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","article-title":"Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy","volume":"129","author":"Kim","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jmsacl.2023.04.002_b0410","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jmsacl.2023.04.002_b0415","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1038\/s41375-018-0157-2","article-title":"Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia","volume":"32","author":"Ernst","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.jmsacl.2023.04.002_b0420","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1751-553X.2009.01208.x","article-title":"The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay","volume":"32","author":"Zhang","year":"2010","journal-title":"Int. J. Lab. Hematol."},{"issue":"6","key":"10.1016\/j.jmsacl.2023.04.002_b0425","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/ijlh.13282","article-title":"Pitfalls in CALR exon 9 mutation detection: A single-center experience in 571 positive patients","volume":"42","author":"Verger","year":"2020","journal-title":"Int. J. Lab. Hematol."},{"issue":"2","key":"10.1016\/j.jmsacl.2023.04.002_b0430","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3324\/haematol.11993","article-title":"Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib","volume":"93","author":"Ernst","year":"2008","journal-title":"Haematologica"},{"issue":"24","key":"10.1016\/j.jmsacl.2023.04.002_b0435","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.jmsacl.2023.04.002_b0440","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1080\/10428190902930496","article-title":"New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"50","author":"Mascarenhas","year":"2009","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"10.1016\/j.jmsacl.2023.04.002_b0445","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1373\/clinchem.2004.031112","article-title":"Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib","volume":"50","author":"Soverini","year":"2004","journal-title":"Clin. Chem."},{"issue":"12","key":"10.1016\/j.jmsacl.2023.04.002_b0450","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jmsacl.2023.04.002_b0455","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17050642","article-title":"Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches","volume":"17","author":"Preuner","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.jmsacl.2023.04.002_b0460","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1111\/j.1349-7006.2010.01627.x","article-title":"Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays","volume":"101","author":"Yin","year":"2010","journal-title":"Cancer Sci."},{"issue":"7","key":"10.1016\/j.jmsacl.2023.04.002_b0465","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/jcp.2011.089193","article-title":"A pyrosequencing-based test for detection and relative quantification of the BCR-ABL1 T315I point mutation","volume":"64","author":"Schumacher","year":"2011","journal-title":"J. Clin. Pathol."},{"issue":"2","key":"10.1016\/j.jmsacl.2023.04.002_b0470","first-page":"2419","article-title":"Molecular screening and the clinical impacts of BCR-ABL KD mutations in patients with imatinib-resistant chronic myeloid leukemia","volume":"15","author":"Kockan","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.jmsacl.2023.04.002_b0475","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1756-8722-4-7","article-title":"A single-tube allele specific-polymerase chain reaction to detect T315I resistant mutation in chronic myeloid leukemia patients","volume":"4","author":"Wongboonma","year":"2011","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.jmsacl.2023.04.002_b0480","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.leukres.2008.08.018","article-title":"Quantitative monitoring of the T315I mutation in patients with chronic myeloid leukemia (CML)","volume":"33","author":"Chomel","year":"2009","journal-title":"Leuk. Res."},{"key":"10.1016\/j.jmsacl.2023.04.002_b0485","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.exphem.2020.01.001","article-title":"Detection of T315I using digital polymerase chain reaction in allogeneic transplant recipients with Ph-positive acute lymphoblastic anemia in the dasatinib era","volume":"81","author":"Akahoshi","year":"2020","journal-title":"Exp. Hematol."},{"issue":"12","key":"10.1016\/j.jmsacl.2023.04.002_b0490","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9123865","article-title":"Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?","volume":"9","author":"Soverini","year":"2020","journal-title":"J. Clin. Med."},{"issue":"10","key":"10.1016\/j.jmsacl.2023.04.002_b0495","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1182\/blood-2011-08-375535","article-title":"Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile","volume":"119","author":"Parker","year":"2012","journal-title":"Blood"}],"container-title":["Journal of Mass Spectrometry and Advances in the Clinical Lab"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667145X23000238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667145X23000238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T07:22:35Z","timestamp":1767770555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667145X23000238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":99,"alternative-id":["S2667145X23000238"],"URL":"https:\/\/doi.org\/10.1016\/j.jmsacl.2023.04.002","relation":{},"ISSN":["2667-145X"],"issn-type":[{"value":"2667-145X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A customized mass array panel for BCR::ABL1 tyrosine kinase domain mutation screening in chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Mass Spectrometry and Advances in the Clinical Lab","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmsacl.2023.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 THE AUTHORS. Publishing services by ELSEVIER B.V. on behalf of MSACL.","name":"copyright","label":"Copyright"}]}}